Please assess the completion status of the following clinical trial:

Trial Title: Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In order to be eligible to participate in this study, an individual must meet all of the following criteria:~  1. Provide signed and dated informed consent form~ 2. Is between 18 and 65 years of age (inclusive; male or female and any race or ethnicity)~ 3. Trigeminal neuropathic pain symptoms for a minimum of 3 months prior to randomization visit, localized in any trigeminal distribution (intraoral or extraoral).~ 4. Meets diagnostic criteria for Trigeminal neuropathic pain with diagnosis based on the International classification of headache disorders ICHD-3 and International classification of Orofacial Pains ICOP.~     * Diagnosed with idiopathic trigeminal neuralgia with concomitant continuous pain per ICDH-3.~    * Diagnosed with Painful posttraumatic trigeminal neuropathy or idiopathic painful trigeminal neuropathy per ICOP. May include:~       * Subjects with a history of persistent pain of idiopathic origin or after dental extractions, mandibular fracture, surgical procedure, implant procedure and root canal therapy.~ 5. Participants must have a minimum mean of average daily pain intensity score of 4/10 in where 0= no pain and 10= maximum pain imaginable on a numerical rating scale (0-10), during the 4 weeks/28 days baseline period prior randomization.~ 6. If taking a prescription medication daily for the management of pain (taken for at least 30 days before baseline), agrees to continue the daily use of the medication throughout the study at the same dosage.~ 7. If taking prescription medication, opioid medication or OTC medications as needed or episodically for the management of pain agrees to discontinue its use prior to the Screening and Baseline Visit.~ 8. If taking OTC pain medications daily agrees to continue its daily use at the same dosage throughout the study.~     • If a participant is taking an over-the-counter medication daily for management of other type of pain or for prophylaxis of myocardial infarction or stroke, the participant will be encouraged to continue the same usage of that medication throughout the study.~ 9. If subjects diagnosed with migraine, are allowed only if episodic, with attacks of duration up to 5 days/month and only using triptans or NSAIDs as an abortive medication.~ 10. Agrees to not start any new prescription medication for the management of trigeminal neuropathic pain or other type of pain throughout the study.~ 11. Agrees to not modify their prescription regimen for current trigeminal neuropathic pain or other types of pain throughout the study~ 12. Agrees not to receive any injection therapy for the management of neuropathic pain or migraine (e.g. nerve blocks, SPG blocks, steroid injections, Botox) during the course of the study~ 13. Agrees not to use any neuromodulatory device for the management of neuropathic pain or migraine during the course of the study~ 14. Agrees not to undergo any surgical procedure for the management of neuropathic pain during the course of the study~ 15. Agrees to not use cognitive behavioral therapy (CBT), biofeedback or acupuncture for the management of pain during the course of the study.~ 16. Females of childbearing potential agree to use one of the following methods of contraception throughout the study: licensed hormonal method, intrauterine device, female or male condoms with contraceptive foam, abstinence, bilateral tubal ligation/occlusion, or vasectomy in partner (if postmenopausal, must not have menstruated for at least 12 consecutive months)~ 17. Willing and able to understand and comply with all study procedures and be available for the duration of the study.~Exclusion Criteria:~1. Participants with a history of congestive heart failure or uncontrolled diabetes.~2. Participants with serious hepatic, respiratory, hematologic or immunologic illnesses, an unstable cardiovascular disease, or any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or Erenumab or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.~3. Participants with high blood pressure, uncontrolled high blood pressure, malignant disease, chronic constipation, any malabsorption disorders such as IBSc or any other severe acute or chronic medical or psychiatric condition (major depression, schizophrenia, dementia) or laboratory finding that may increase the risk associated with trial participation with Erenumab, that in the judgement of the investigators would interfere with study assessments and/or would make the participant inappropriate for entry into this trial.~4. Participants with active malignancy of any type or a history a malignancy (with exception of participants with malignancy surgically removed with no evidence of recurrence within 5 years before enrollment.~5. Participants with evidence or a history of drug or alcohol abuse within the past 12 months or has been diagnosed with a substance abuse disorder.~6. Participants with dental pain (determined pain of odontogenic/periodontal origin).~7. Participants with significant neurological disorders.~8. Patients with chronic migraine with and w/o aura following the ICHD-3 criteria treated or not treated with medication~   • Without excluding headache attributed to TMD~9. Participants currently taking or have previously taken Erenumab or other CGRP monoclonal antibody (mAmb) or currently taking a CGRP-Receptor antagonist (gepants) for migraine prevention.~10. Patients with hypersensitivity to Erenumab~11. Participants with trigeminal neuropathic pain taken medications for the management of trigeminal neuropathic pain in where daily dosage has been modified within three weeks before baseline.~12. Neuroimaging showing the presence of neurovascular compression or AV malformation.~13. Neuroimaging showing the presence of intracranial pathology (i.e. multiple sclerosis, tumor).~14. Presence of extracranial pathology in the area of pain (tumor, lesion).~15. Has been treated with another investigational drug or treatment within 30 days prior to the Screening and Baseline Visit~16. Has commenced a new daily prescription medication for the management of pain within 30 days prior to the Screening and Baseline Visit~17. Currently taking opioid medication whether episodically or daily, within 30 days prior to the Screening and Baseline Visit.~18. Patients sensitive to Latex~19. If planning to become pregnant, pregnant or breastfeeding.~20. Anything that, in the opinion of the investigator, would place the participant at increased risk or impede the participant's full compliance with or completion of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab-aooe (Type: ACTIVE_COMPARATOR): Erenumab-aooe 140 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®
- Placebo (Type: PLACEBO_COMPARATOR): Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 andvisit 3 for a total of 3 cycles.~Other name: Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues